151 related articles for article (PubMed ID: 3197751)
1. Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.
Marasini B; Biondi ML; Bianchi E; Dell'Orto P; Agostoni A
Eur J Clin Pharmacol; 1988; 35(4):419-21. PubMed ID: 3197751
[TBL] [Abstract][Full Text] [Related]
2. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
Arneklo-Nobin B; Elmér O; Akesson A
Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
Marasini B; Biondi ML; Mollica R
Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
[TBL] [Abstract][Full Text] [Related]
4. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
5. Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon.
Biondi ML; Marasini B; Bianchi E; Agostoni A
Int J Cardiol; 1988 Jun; 19(3):335-9. PubMed ID: 3397197
[TBL] [Abstract][Full Text] [Related]
6. The use of the selective serotonin S2 receptor antagonist Ketanserin in the treatment of Raynaud's phenomenon.
Dormandy JA; Berent A; Downes SJ
Eur J Vasc Surg; 1988 Dec; 2(6):371-5. PubMed ID: 3075559
[TBL] [Abstract][Full Text] [Related]
7. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
Engelhart M
Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
[TBL] [Abstract][Full Text] [Related]
8. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
Pope J; Fenlon D; Thompson A; Shea B; Furst D; Wells G; Silman A
Cochrane Database Syst Rev; 2000; 1998(2):CD000954. PubMed ID: 10796396
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
[TBL] [Abstract][Full Text] [Related]
10. International study of ketanserin in Raynaud's phenomenon.
Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of ketanserin, a selective antagonist of the serotonin (5-HT2) receptors, in primary and secondary Raynaud's phenomenon.
Meloni F; Transi MG; Sciacca V; De Felice C; Bagarone A; Sciacca A
Angiology; 1987 Jul; 38(7):530-6. PubMed ID: 3619126
[TBL] [Abstract][Full Text] [Related]
12. Platelet serotonin in systemic sclerosis.
Klimiuk PS; Grennan A; Weinkove C; Jayson MI
Ann Rheum Dis; 1989 Jul; 48(7):586-9. PubMed ID: 2774700
[TBL] [Abstract][Full Text] [Related]
13. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
Longstaff J; Gush R; Williams EH; Jayson MI
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon.
Arosio E; Montesi G; Zannoni M; Paluani F; Lechi A
Angiology; 1989 Jul; 40(7):633-8. PubMed ID: 2662829
[TBL] [Abstract][Full Text] [Related]
15. Ketanserin and capillary flow in Raynaud's phenomenon.
Tooke JE; Williams SA; Rawlinson DW; Black C
Int J Microcirc Clin Exp; 1990 Aug; 9(3):249-55. PubMed ID: 2394546
[TBL] [Abstract][Full Text] [Related]
16. Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon.
Marasini B; Bassani C
Br J Clin Pharmacol; 1990 Dec; 30(6):847-51. PubMed ID: 2288831
[TBL] [Abstract][Full Text] [Related]
17. Abnormal platelet aggregation in patients with Raynaud's phenomenon.
Biondi ML; Marasini B
J Clin Pathol; 1989 Jul; 42(7):716-8. PubMed ID: 2760232
[TBL] [Abstract][Full Text] [Related]
18. Treatment of the Raynaud's phenomenon with piracetam.
Moriau M; Lavenne-Pardonge E; Crasborn L; von Frenckell R; Col-Debeys C
Arzneimittelforschung; 1993 May; 43(5):526-35. PubMed ID: 8328997
[TBL] [Abstract][Full Text] [Related]
19. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Raynaud's phenomenon with ketanserin in patients with connective tissue disorders.
Roald OK; Seem E
Br Med J (Clin Res Ed); 1984 Sep; 289(6445):577-9. PubMed ID: 6432198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
